替诺福韦与妊娠期乙型肝炎病毒传播:一项随机临床试验
在中国7家三级医院开展的开放标签、两组、随机、非劣效性临床试验,纳入280例HBV DNA>200 000 IU/mL的孕妇。实验组自 gestational week 16 开始TDF联合婴儿乙肝疫苗接种,标准组自 week 28 开始TDF联合婴儿HBIG和疫苗接种,实验组母婴传播率0.76%(1/131)vs 标准组0%(0/142),组间差异0.76%(90%CI上限1.74%),符合非劣效性。
要点
- 实验组自 gestational week 16 开始TDF联合婴儿疫苗接种,母婴传播率0.76%(1/131),标准组0%(0/142)。
- 组间差异0.76%(90%CI上限1.74%),符合预设3%的非劣效性界值。
- 先天性缺陷/畸形率实验组2.3%(3/131)vs 标准组6.3%(9/142),差异4%(95%CI -8.8%至0.7%)。
核心结论
- 在HBV高病毒载量孕妇中,自 gestational week 16 开始TDF联合婴儿HBV疫苗接种非劣效于自 week 28 开始TDF联合婴儿HBIG和疫苗接种。
- 作者认为这些结果支持在HBIG不可及的地区自 gestational week 16 开始TDF联合婴儿HBV疫苗以预防HBV母婴传播。
研究设计与样本
- 开放标签、两组、随机、非劣效性临床试验,在中国7家三级医院开展。
- 2018年6月4日至2021年2月8日纳入280例HBV DNA>200 000 IU/mL的孕妇(均识别为女性),平均年龄28岁,入组时平均孕周16周。
- 最终随访于2022年3月1日完成;265例(95%)完成研究。
主要发现
- 在全活产婴儿中采用末次观测值结转,实验组母婴传播率0.76%(1/131)vs 标准组0%(0/142)。
- 符合方案分析中,实验组母婴传播率0%(0/124)vs 标准组0%(0/141)。
- 全活产婴儿组间差异0.76%(双侧90%CI上限1.74%),符合方案分析组间差异0%(双侧90%CI上限1.43%),两项比较均符合非劣效性标准。
- 先天性缺陷和畸形率实验组2.3%(3/131)vs 标准组6.3%(9/142),差异4%(双侧95%CI -8.8%至0.7%)。
关键数值与推荐
- 主要结局为婴儿28周龄时可检测HBV DNA>20 IU/mL或HBsAg阳性定义的母婴传播率。
- 非劣效性标准为实验组母婴传播率较标准组增加的绝对差异不超过3%,以双侧90%CI上限衡量。
临床怎么用
- 作者认为这些结果支持在HBIG不可及的地区自 gestational week 16 开始TDF联合婴儿HBV疫苗以预防HBV母婴传播。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Standard care for preventing mother-to-child transmission (MTCT) of hepatitis B virus (HBV) in highly viremic mothers consists of maternal antiviral prophylaxis beginning at gestational week 28 combined with an HBV vaccine series and HBV immune globulin (HBIG) at birth. However, HBIG is unavailable in some resource-limited areas. OBJECTIVE: To determine whether initiating tenofovir disoproxil fumarate (TDF) at gestational week 16 combined with HBV vaccinations for infants is noninferior to the standard care of TDF at gestational week 28 combined with HBV vaccinations and HBIG for infants in preventing MTCT in mothers with HBV and high levels of viremia. DESIGN, SETTING, AND PARTICIPANTS: An unblinded, 2-group, randomized, noninferiority clinical trial was conducted in 7 tertiary care hospitals in China. A total of 280 pregnant individuals (who all identified as women) with HBV DNA levels greater than 200 000 IU/mL were enrolled between June 4, 2018, and February 8, 2021. The final follow-up occurred on March 1, 2022. INTERVENTIONS: Pregnant individuals were randomly assigned to receive either TDF starting at gestational week 16 with HBV vaccinations for the infant or TDF starting at gestational week 28 with HBV vaccinations and HBIG administered to the infant. MAIN OUTCOMES AND MEASURES: The primary outcome was the MTCT rate, defined as detectable HBV DNA greater than 20 IU/mL or hepatitis B surface antigen positivity in infants at age 28 weeks. Noninferiority was established if the MTCT rate in the experimental group did not increase by more than an absolute difference of 3% compared with the standard care group, as measured by the upper limit of the 2-sided 90% CI. RESULTS: Among 280 pregnant individuals who enrolled in the trial (mean age, 28 years; mean gestational age at enrollment, 16 weeks), 265 (95%) completed the study. Among all live-born infants, using the last observation carried forward, the MTCT rate was 0.76% (1/131) in the experimental group and 0% (0/142) in the standard care group. In the per-protocol analysis, the MTCT rate was 0% (0/124) in the experimental group and 0% (0/141) in the standard care group. The between-group difference was 0.76% (upper limit of the 2-sided 90% CI, 1.74%) in all live-born infants and 0% (upper limit of the 2-sided 90% CI, 1.43%) in the per-protocol analysis. Both comparisons met the criterion for noninferiority. Rates of congenital defects and malformations were 2.3% (3/131) in the experimental group and 6.3% (9/142) in the standard care group (difference, 4% [2-sided 95% CI, -8.8% to 0.7%]). CONCLUSIONS AND RELEVANCE: Among pregnant women with HBV and high levels of viremia, TDF beginning at gestational week 16 combined with HBV vaccination for infants was noninferior to the standard care of TDF beginning at gestational week 28 combined with HBIG and HBV vaccination for infants. These results support beginning TDF at gestational week 16 combined with infant HBV vaccine to prevent MTCT of HBV in geographic areas where HBIG is not available. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03476083.
引用
- Pan CQ, Dai E, Mo Z, et al. Tenofovir and Hepatitis B Virus Transmission During Pregnancy: A Randomized Clinical Trial. JAMA. 2025. PMID: 39540799. doi:10.1001/jama.2024.22952
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。